VICTORION-INITIATE supports early inclisiran treatment in ASCVD LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD US patients missing out on bempedoic acid Evolocumab benefits in patients with autoimmune and inflammatory diseases CLEAR Outcomes confirms bempedoic acid benefits for recurrent CV events PCSK9i access remains challenging in USA

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Question of the Month

Combination therapy in familial hypercholesterolaemia: what can we gain from novel agents?

LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?
Professor John Chapman

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed

VICTORION-INITIATE supports early inclisiran treatment in ASCVD LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD Atherogenicity of apoB-containing particles: The Trilogy of LDL, Lp(a) and remnants CLEAR Outcomes confirms bempedoic acid benefits for recurrent CV events Lp(a) and plaque progression: Insights from imaging What do you do after a Statin? So many choices… what is yours? Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low? Evolocumab benefits in patients with autoimmune and inflammatory diseases ORION-8: Inclisiran shows efficacy and safety beyond six years FOURIER-OLE shows greater MACE reduction in multivessel disease

Most viewed

VICTORION-INITIATE supports early inclisiran treatment in ASCVD

Hot Topics

18th Virtual Closed Scientific Expert Meeting of the Editorial Board

Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention
Professor Alberto Zambon proposes a novel ‘fast to target’ paradigm for patients at very high cardiovascular risk.

Watch now

View all presentations »

From the Editors

Lerodalcibep: What does LIBerate-HeFH tell us?

Prof Derick Raal Professor Derick Raal discusses lerodalcibep data from the LIBerate-HeFH trial and explains what the results mean to practising clinicians.